{"disease":{"id":"polypoid-choroidal-vasculopathy-pcv","name":"polypoid choroidal vasculopathy pcv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03244657","title":"Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT07365371","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05666804","title":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07461441","title":"Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}